All News

Found 123 articles

• Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

  8/16/2021

  Gracell Biotechnologies Inc. today announced an exclusive license agreement with FutureGen Biopharm ("FutureGen"), an innovative biopharmaceutical company, to develop engineered immune cell therapies targeting Claudin 18.2 ("CLDN18.2") in solid tumors.

• Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021

  8/3/2021

  Gracell Biotechnologies Inc. today announced that it will release financial results for the second quarter ended June 30, 2021, prior to the open of the U.S. financial markets on Tuesday, August 17.

• 

  U.S. Waves Red Flag at China, Halting IPOs of Chinese Companies

  7/30/2021

  The U.S. Securities and Exchange Commission has halted registrations of U.S. initial public offerings (IPOs) by Chinese companies. 

• Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology Conference

  7/26/2021

  Gracell Biotechnologies Inc. today announced that it will participate in the BTIG Virtual Biotechnology Conference 2021 (details below).

• Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

  6/2/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has rescheduled its conference call and webcast to Monday, June 14, 2021 @ 8:00 am ET

• Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma

  5/26/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it host a key opinion leader (KOL) webinar on the challenges of treating High Risk Multiple Myeloma and a potential novel approach on Friday, June 11, 2021 at 8:00am Eastern Time.

• Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June

  5/25/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences

• Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT

  5/21/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA/CD19

• Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

  5/19/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated results of their first-in-human multicenter study of GC012F for the treatment of multiple myeloma

• Gracell Biotechnologies Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update

  5/17/2021

  Reported updated long-term follow-up data for TruUCAR-enabled CD7-targeted CAR-T product candidate GC027 for the treatment of T-ALL at AACR 2021 Annual Meeting Signed agreement with Lonza to manufacture FasTCAR-enabled product candidates in the U.S. Completed initial public offering of ADSs for net proceeds of US$220 million; US$331.1 million in cash as of March 31, 2021

• Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer

  5/10/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Dr. Jenny (Yajin) Ni as its Chief Technology Officer (CTO).

• Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May 2021

  4/30/2021

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that it will participate in the following upcoming virtual conferences

• Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020

  4/23/2021

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission on April 23, 2021.

• Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting

  4/10/2021

  Gracell Biotechnologies Inc. presented updated long-term follow-up data on their TruUCAR-enabled allogeneic product candidate GC027 for the treatment of adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia in an e-poster presentation at the 2021 American Association for Cancer Research Annual Meeting on April 10.

• Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference

  4/5/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference (details below).

• Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

  3/31/2021

   Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enrolled the first patient in their pivotal Phase 1/2 clinical study of GC007g

• Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.

  3/31/2021

  Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has entered into a Manufacturing Service Agreement (MSA) with Lonza

• Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day

  3/17/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it will participate in the upcoming 2021 Virtual Wells Fargo Biotech Corporate Access Day.

• Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update

  3/9/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today reported its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2020 and recent business highlights

• Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021

  2/23/2021

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it plans to release financial results for the fourth quarter and year ended December 31, 2020